| Bleier, Joshua |
| Active, not recruiting | N/A | 40 | US | Neuromodulation | Boomerang Medical | IBD | 12/24 | 12/24 | | |
NCT04940611: A Study of Surgical Interventions in Fistulizing Conditions |
|
|
| Active, not recruiting | N/A | 750 | Europe, Canada, US, RoW | | Takeda | Crohns Disease, Fistula, Rectovaginal Fistula, Complex Perianal Fistula, Complex Cryptoglandular Fistula | 05/26 | 05/26 | | |
| Wu, Jason |
NCT05051761: Study to Evaluate the Safety and Efficacy of Jaktinib in Adults With Alopecia Areata |
|
|
| Active, not recruiting | 3 | 425 | RoW | Jaktinib, placebo | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Alopecia Areata | 12/24 | 12/24 | | |
NCT05676242: A Phase III Extended Clinical Trial of Jaktinib Hydrochloride Tablets in the Treatment of Moderate and Severe Atopic Dermatitis |
|
|
| Recruiting | 3 | 400 | RoW | Jaktinib Hydrochloride Tablet | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Atopic Dermatitis | 12/24 | 12/24 | | |
NCT05526222: A Phase III Study of Jaktinib in Adults With Moderate and Severe Atopic Dermatitis |
|
|
| Recruiting | 3 | 438 | RoW | Jaktinib Hydrochloride Tablet | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Atopic Dermatitis | 06/25 | 09/25 | | |
NCT04312594: Study of Jaktinib Hydrochloride Tablets in Participants With Idiopathic Pulmonary Fibrosis |
|
|
| Completed | 2 | 91 | RoW | Jaktinib Hydrochloride Tablets, Jaktinib, Placebo | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Idiopathic Pulmonary Fibrosis | 06/22 | 06/22 | | |
NCT06558227: Study of ZG005 Combined With Bevacizumab Versus Sintilimab Combined With Bevacizumab in Advanced Hepatocellular Carcinoma |
|
|
| Recruiting | 2 | 90 | RoW | ZG005 for Injection, ZG005, Bevacizumab, Avastin, Sintilimab, 达攸同 | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Hepatocellular Carcinoma | 09/26 | 10/26 | | |
NCT06237400: A Study of ZG19018 in Patients With KRAS G12C Mutant Advanced Solid Tumors. |
|
|
| Recruiting | 1/2 | 110 | RoW | ZG19018 | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | KRAS G12C Mutant Advanced Solid Tumors | 05/25 | 05/25 | | |
NCT06233292: A Study of ZG005 in Patients With Advanced Solid Tumors |
|
|
| Recruiting | 1/2 | 484 | RoW | ZG005 Powder for Injection, ZG005 | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Solid Tumors | 01/26 | 01/26 | | |
NCT06237413: A Study of ZG2001 in Participants With KRAS Mutated Advanced Solid Tumours |
|
|
| Recruiting | 1/2 | 110 | RoW | ZG2001 Tosilate Tablets, ZG2001 | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Solid Tumor, KRAS Mutation-Related Tumors | 02/26 | 02/26 | | |
NCT06241235: Study of ZG005 in Combination With Paclitaxel＋Platinum-based ± Bevacizumab in Patients With Advanced Cervical Carcinoma |
|
|
| Recruiting | 1/2 | 48 | RoW | ZG005 Powder for Injection, ZG005, Paclitaxel, Bevacizumab, Cisplatin, Carboplatin | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Cervical Carcinoma | 05/26 | 05/26 | | |
NCT06239298: A Study of ZG005 Combined With Donafenib in Patients With Advanced Solid Tumor |
|
|
| Recruiting | 1/2 | 130 | RoW | ZG005 Powder for Injection, ZG005, Donafenib Tosilate Tablets, Donafenib | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Solid Tumor | 03/26 | 05/26 | | |
ZG005-004, NCT06372626: Study of ZG005 in Combination With Etoposide and Cisplatin in Participants With Advanced Neuroendocrine Carcinoma. |
|
|
| Recruiting | 1/2 | 93 | RoW | ZG005, Etoposide, Cisplatin, Placebo | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Neuroendocrine Carcinoma | 07/26 | 08/26 | | |
NCT06440057: Dose Escalation Study of ZG006 in Participants With Advanced Small Cell Lung Cancer or Neuroendocrine Carcinoma, Followed by Dose Expansion Study in Participants With Neuroendocrine Carcinoma. |
|
|
| Recruiting | 1/2 | 78 | RoW | ZG006 | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Neuroendocrine Carcinoma | 05/26 | 07/26 | | |
NCT06283719: Dose Escalation Study of ZG006 in Participants With Advanced Small Cell Lung Cancer or Neuroendocrine Carcinoma, Followed by Dose Expansion Study in Participants With Advanced Small Cell Lung Cancer |
|
|
| Recruiting | 1/2 | 105 | RoW | ZG006 | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Small Cell Lung Cancer, Neuroendocrine Cancer | 04/26 | 04/26 | | |
NCT05584800: Study of ZGGS18 in Patients With Advanced Solid Tumors |
|
|
| Recruiting | 1/2 | 222 | RoW | ZGGS18 for Injection | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Advanced Solid Tumor | 11/25 | 11/25 | | |
NCT06246695: A Study to Evaluate the Effect of Itraconazole and Rifampicin on the Pharmacokinetics of Jaktinib in Healthy Volunteers |
|
|
| Completed | 1 | 40 | RoW | Jaktinib Hydrochloride Tablets, Jaktinib, Itraconazole capsule, Itraconazole, Rifampicin Capsules, Rifampicin | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Healthy Volunteers | 01/22 | 01/22 | | |
| Recruiting | 1 | 26 | US | Jaktinib Hydrochloride Tablet | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Myelofibrosis | 05/25 | 11/25 | | |
NCT06132243: Comparative Study on Pharmacokinetics of Two Formulations of Jaktinib in Healthy Adults Under Fasting Conditions |
|
|
| Completed | 1 | 52 | RoW | Jaktinib Hydrochloride Tablets, Jaktinib | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Myelofibrosis | 12/23 | 12/23 | | |
NCT05877664: Study of ZG0895.HCl in Patients With Advanced Solid Tumors |
|
|
| Recruiting | 1 | 60 | RoW | ZG0895 Hydrochloride for Injection, ZG0895.HCl | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Advanced Solid Tumor | 06/26 | 06/26 | | |
| Active, not recruiting | N/A | 40 | US | Neuromodulation | Boomerang Medical | IBD | 12/24 | 12/24 | | |
